en · de · es · pt
lab-handbook.peptides6908.com › Info › Detection, Regulation, And Quality Context — Background and Details

Detection, Regulation, And Quality Context — Background and Details

By Editorial Desk · published 2025-09-28 · last reviewed 2025-11-06 · Info

If you have been reading about PPAR delta and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-11-06. Where a claim depends on a specific study, the study is described rather than over-claimed.

Detection, Regulation, and Quality Context

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Background and Research Context

Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.

PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.

Cardarine at a glance

PropertyValueNotes
WADA classificationS4 Hormone and Metabolic ModulatorsProhibited at all times in sport.
Drug approval statusNot approved in major jurisdictionsNo accepted therapeutic indication.
Common detection methodLC-MS/MSDetects parent compound and metabolites.
Typical test matrixUrine or bloodUrine is common in anti-doping testing.
Product labelingResearch chemical or supplementOften not independently verified.

Mechanism and Research Context

Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.

In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.

Related pages on this site

Background and Regulatory History

Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.

GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.

Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.

Preclinical Findings and Safety Signals

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.

Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.

Reference notes

=== Endogenous inhibitors === MMP activity is regulated at various levels for example by endogenous inhibitors like α2-macroglobulin and the tissue inhibitors of metalloproteinases (TIMPs). α2-macroglobulin regulates a broad spectrum of proteases, while TIMPs are more specific endogenous MMP inhibitors. α2-macroglobulin is an abundant plasma protein that acts in tissue fluids. The plasma glycoprotein consists of four subunits. α2-macroglobulin does not inhibit the activation of MMPs or the MMPs themselves. It entraps proteinases like MMPs and forms a complex with them. The complex is endocytosed and cleared by a low-density lipoprotein-receptor-related protein. In humans, 4 different TIMPs have been found. They are secreted proteins of low-molecular weight. TIMPs bind noncovalently to the active site of MMPs. Changes of TIMP levels are considered to play a role in pathological conditions associated with unbalanced MMP activities. TIMPs consist of 184-194 amino acids. These inhibitors are subdivided into two domains N-terminal and C-terminal. The N-terminal regions of the four TIMPs share a common structure. They all contain twelve cysteine residues that form six disulfide bonds. These bonds are critical for the conformation of the N-terminal and its MMP-inhibitory activities. The C-terminals of the TIMPs differ from each other. The N-terminal subunit is capable of inhibiting MMPs. The TIMP molecule form fits into the active site of an MMP. The TIMP contact the catalytic cleft of the MMP in a similarly as a substrate.

On 1 March, the Department of Food and Veterinary of Lithuania announced that horse meat was found in three canned beef brands sold by Latvian company Kuršu Zeme. Canned beef made by the Latvian company was removed from sale in Lithuania. === Wiljo Import en Export B.V. and Vleesgroothandel Willy Selten B.V. === On 10 April 2013, it was reported that two Dutch trading companies, owned by the same person whom food safety officials had previously investigated, may have supplied 50,000 metric tonnes of adulterated beef containing horse meat since January 2011. On 7 February 2013, it was revealed by the Food Standards Agency that the Findus beef lasagne range in the UK, France, Norway, and Sweden, and the shepherd's pie and moussaka ranges in France, contained horse meat without proper declaration or official scrutiny. The contamination may have gone on since summer 2012 according to a leaked document.

Non-synonymous is the variant in exons that change the amino acid sequence encoded by the gene, including single base changes and non frameshift indels. It has been extremely investigated the function of non-synonymous variants on protein and many algorithms have been developed to predict the deleteriousness and pathogenesis of single nucleotide variants (SNVs). Classical bioinformatics tools, such as SIFT, Polyphen and MutationTaster, successfully predict the functional consequence of non-synonymous substitution. PopViz webserver provides a gene-centric approach to visualize the mutation damage prediction scores (CADD, SIFT, PolyPhen-2) or the population genetics (minor allele frequency) versus the amino acid positions of all coding variants of a certain human gene. PopViz is also cross-linked with UniProt database, where the protein domain information can be found, and to then identify the predicted deleterious variants fall into these protein domains on the PopViz plot.

Sources: en.wikipedia.org

Notes from published material

=== Miscellaneous eutherian research === Lopatin & Averianov (2026) report the discovery of a new eutherian petrosal bone from the Lower Cretaceous (Aptian-Albian) strata from the Khovoor locality (Mongolia), and interpret the two eutherian petrosal reported from the Khovoor locality to date as likely belonging to two distinct taxa, possibly Prokennalestes minor and Hovurlestes noyon. Description of the endocranial anatomy of Leptictis dakotensis and L. haydeni is published by Van Gent et al. (2026). Raynaud et al. (2026) describe fossil material of Coryphodon from the Eocene strata from the Le Quesnoy site (France), compare the diagnostic characters of C. eocaenus, C. anthracoideus and C. oweni, and interpret the latter two species as junior synonyms of C. eocaenus.

=== Pharmacokinetics === If the dosage guidelines are followed, the drug reaches peak plasma levels after two hours and is completely cleared from plasma two hours after termination of the infusion period. Endogenous plasma protease inhibitors deactivate drotrecogin. Therefore, no dose adjustment is needed in elderly patients, or in patients with renal or hepatic dysfunction.

=== Quigley Company asbestos settlement (2013) === The Quigley Company, which sold asbestos-containing insulation products until the early 1970s, was acquired by Pfizer in 1968. In June 2013, asbestos victims and Pfizer negotiated a settlement that required Pfizer to pay a total of $964 million: $430 million to 80% of existing plaintiffs and place an additional $535 million into a settlement trust that will compensate future plaintiffs as well as the remaining 20% of plaintiffs with claims against Pfizer and Quigley. Of that $535 million, $405 million is in a 40-year note from Pfizer, while $100 million is from insurance policies.

Bacteria (e.g. Mycobacterium tuberculosis, Staphylococcus aureus, Escherichia coli, Clostridium botulinum, and Salmonella spp.) Viruses and subviral agents such as viroids and prions. (E.g. HIV, Rhinovirus, Lyssaviruses such as Rabies virus, Ebolavirus and Severe acute respiratory syndrome coronavirus 2) Fungi, further subclassified into: Ascomycota, including yeasts such as Candida (the most common fungal infection); filamentous fungi such as Aspergillus; Pneumocystis species; and dermatophytes, a group of organisms causing infection of skin and other superficial structures in humans. Basidiomycota, including the human-pathogenic genus Cryptococcus. Parasites, which are usually divided into: Unicellular organisms (e.g. malaria, Toxoplasma, Babesia) Macroparasites (worms or helminths) including nematodes such as parasitic roundworms and pinworms, tapeworms (cestodes), and flukes (trematodes, such as schistosomes). Diseases caused by helminths are sometimes termed infestations, but are sometimes called infections. Arthropods such as ticks, mites, fleas, and lice, can also cause human disease, which conceptually are similar to infections, but invasion of a human or animal body by these macroparasites is usually termed infestation.

Sources: en.wikipedia.org

Background from the literature

The chain of reactions that generate reactive oxygen species (ROS) results in oxidative stress, which ultimately causes cell damage. Type II pathway of photodynamic reaction: After PS is excited into T1 state, the energy is transferred directly between PS and O2. This interaction transforms the oxygen molecules into a highly reactive form known as singlet oxygen. Singlet oxygen possesses potent oxidizing properties, making it extremely effective in reacting with and damaging cellular components. However, this reaction is selective; while most cellular components exist in a less reactive singlet state and remain unaffected, the singlet oxygen specifically targets and reacts with oxygen molecules in the cell cytoplasm. PDT is used to treat cancer across diverse types and sites. A unique feature of PDT is that photosensitizers tend to accumulate more selectively in cancer cells than in normal cells. The high affinity of photosensitizers to low-density lipoprotein (LDL) allows for selectivity. LDL acts as a carrier, allowing photosensitizers to travel into cancerous tissues. The interaction between photosensitizers and LDL makes it easier for therapeutic agents to reach the right places, which makes PDT more effective against cancer.

Individual quick freezing is a descriptive term that includes all forms of freezing that is "individual" (not in a whole block) and "quick" (taking a maximum of several minutes). It may correspond to cryogenic freezing, fluidized bed freezing, or any other technique that meets the definition.

The production was held at the Eugene O'Neill Theatre in New York City to raise money for the American Foundation for Equal Rights. Freeman had a lead role in the 2012 drama The Magic of Belle Isle, as an alcoholic novelist trying to write again. The film fared poorly with critics, gaining only a 29% approval rating on Rotten Tomatoes. Lastly in 2012, Freeman reprised his role as Lucius Fox for the third time in The Dark Knight Rises. A number of box office hits were released in 2013. Freeman appeared in the action-thriller Olympus Has Fallen, the first installment in what would become the Has Fallen film series; he portrays Speaker of the House Allan Trumbull. The San Francisco Chronicle critic gave Olympus Has Fallen 3 out of 4 stars and opined that Freeman gave an amicable supporting performance. He then starred in the science fiction drama Oblivion, with co-star Tom Cruise, as veteran soldier Malcolm Beech, and appeared in the thriller Now You See Me, as an ex-magician. Lastly, he played a retiree in Last Vegas, with co-stars Michael Douglas, Robert De Niro, Kevin Kline, and Mary Steenburgen. Filmed in Las Vegas and Atlanta, Last Vegas was praised for its cast's chemistry, and one critic thought Freeman brought the most amusement. In 2014, Freeman voiced the character Vitruvius in The Lego Movie, a commercially successful 3D animation. He starred in Transcendence, a science fiction thriller directed by Wally Pfister in his directorial debut, in which Freeman plays scientist Joseph Tagger. Critic reviews of the film were generally mixed, according to Metacritic.

Sources: en.wikipedia.org

Frequently asked questions

How is cardarine detected in anti-doping tests?

Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.

Is cardarine legal?

Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.

What does a certificate of analysis show?

A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.

What is cardarine?

Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.

Network